Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

Evolved Aliphatic Halogenases Enable Regiocomplementary C-H Functionalization of Pharmaceutically Relevant.

Hayashi T, Ligibel M, Sager E, Voss M, Hunziker J, Schroer K, Snajdrova R, Buller R.

Angew Chem Int Ed Engl. 2019 Oct 7. doi: 10.1002/anie.201907245. [Epub ahead of print]

PMID:
31589798
2.

Enzymatic PET Degradation.

Papadopoulou A, Hecht K, Buller R.

Chimia (Aarau). 2019 Sep 18;73(9):743-749. doi: 10.2533/chimia.2019.743. Review.

PMID:
31514776
3.

Highly conserved influenza T cell epitopes induce broadly protective immunity.

Eickhoff CS, Terry FE, Peng L, Meza KA, Sakala IG, Van Aartsen D, Moise L, Martin WD, Schriewer J, Buller RM, De Groot AS, Hoft DF.

Vaccine. 2019 Aug 23;37(36):5371-5381. doi: 10.1016/j.vaccine.2019.07.033. Epub 2019 Jul 19.

PMID:
31331771
4.

CCR5 is a required signaling receptor for macrophage expression of inflammatory genes in response to viral double-stranded RNA.

Shaheen ZR, Christmann BS, Stafford JD, Moran JM, Buller RML, Corbett JA.

Am J Physiol Regul Integr Comp Physiol. 2019 May 1;316(5):R525-R534. doi: 10.1152/ajpregu.00019.2019. Epub 2019 Feb 27.

PMID:
30811246
5.

Novel Old Yellow Enzyme Subclasses.

Peters C, Frasson D, Sievers M, Buller R.

Chembiochem. 2019 Jun 14;20(12):1569-1577. doi: 10.1002/cbic.201800770. Epub 2019 May 8.

PMID:
30758121
6.

Linear enzyme cascade for the production of (-)-iso-isopulegol.

Peters C, Buller R.

Z Naturforsch C J Biosci. 2019 Feb 25;74(3-4):63-70. doi: 10.1515/znc-2018-0146.

PMID:
30645192
7.

Directed evolution of carbon-hydrogen bond activating enzymes.

Frey R, Hayashi T, Buller RM.

Curr Opin Biotechnol. 2018 Dec 21;60:29-38. doi: 10.1016/j.copbio.2018.12.004. [Epub ahead of print] Review.

PMID:
30583278
8.

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents.

Ananthula HK, Parker S, Touchette E, Buller RM, Patel G, Kalman D, Salzer JS, Gallardo-Romero N, Olson V, Damon IK, Moir-Savitz T, Sallans L, Werner MH, Sherwin CM, Desai PB.

BMC Pharmacol Toxicol. 2018 Dec 4;19(1):80. doi: 10.1186/s40360-018-0270-x.

9.

Identifying and Tracking Low-Frequency Virus-Specific TCR Clonotypes Using High-Throughput Sequencing.

Wolf K, Hether T, Gilchuk P, Kumar A, Rajeh A, Schiebout C, Maybruck J, Buller RM, Ahn TH, Joyce S, DiPaolo RJ.

Cell Rep. 2018 Nov 27;25(9):2369-2378.e4. doi: 10.1016/j.celrep.2018.11.009.

10.

Detection of Viruses in Clinical Samples by Use of Metagenomic Sequencing and Targeted Sequence Capture.

Wylie KM, Wylie TN, Buller R, Herter B, Cannella MT, Storch GA.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e01123-18. doi: 10.1128/JCM.01123-18. Print 2018 Dec.

11.

The Virology of Taterapox Virus In Vitro.

Parker S, Camilo de Oliveira L, Lefkowitz EJ, Hendrickson RC, Bonjardim CA, Wold WSM, Hartzler H, Crump R, Buller RM.

Viruses. 2018 Aug 29;10(9). pii: E463. doi: 10.3390/v10090463.

12.

Heartland Virus and Hemophagocytic Lymphohistiocytosis in Immunocompromised Patient, Missouri, USA.

Carlson AL, Pastula DM, Lambert AJ, Staples JE, Muehlenbachs A, Turabelidze G, Eby CS, Keller J, Hess B, Buller RS, Storch GA, Byrnes K, Dehner L, Kirmani N, Kuhlmann FM.

Emerg Infect Dis. 2018 May;24(5):893-897. doi: 10.3201/eid2405.171802.

13.

Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.

Long KR, Lomonosova E, Li Q, Ponzar NL, Villa JA, Touchette E, Rapp S, Liley RM, Murelli RP, Grigoryan A, Buller RM, Wilson L, Bial J, Sagartz JE, Tavis JE.

Antiviral Res. 2018 Jan;149:41-47. doi: 10.1016/j.antiviral.2017.11.008. Epub 2017 Nov 10.

14.

Evaluation of Taterapox Virus in Small Animals.

Parker S, Crump R, Hartzler H, Buller RM.

Viruses. 2017 Aug 1;9(8). pii: E203. doi: 10.3390/v9080203.

15.

Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: A multicenter prospective cohort study.

Parrish A, Fenchel M, Storch GA, Buller R, Mason S, Williams N, Ikle D, Conrad C, Faro A, Goldfarb S, Hayes D Jr, Melicoff-Portillo E, Schecter M, Visner G, Sweet S, Danziger-Isakov L; Clinical Trials in Organ Transplantation in Children (CTOTC-03).

Pediatr Transplant. 2017 Sep;21(6). doi: 10.1111/petr.13011. Epub 2017 Jun 21.

16.

Multicenter Clinical Evaluation of the Luminex Aries Flu A/B & RSV Assay for Pediatric and Adult Respiratory Tract Specimens.

Juretschko S, Mahony J, Buller RS, Manji R, Dunbar S, Walker K, Rao A.

J Clin Microbiol. 2017 Aug;55(8):2431-2438. doi: 10.1128/JCM.00318-17. Epub 2017 May 24.

17.

Challenges and opportunities for the development of new antipsychotic drugs.

Forray C, Buller R.

Biochem Pharmacol. 2017 Nov 1;143:10-24. doi: 10.1016/j.bcp.2017.05.009. Epub 2017 May 15. Review.

PMID:
28522405
18.

Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

Crump R, Korom M, Buller RM, Parker S.

Antiviral Res. 2017 Mar;139:112-116. doi: 10.1016/j.antiviral.2016.12.015. Epub 2016 Dec 27.

19.

Tissue polymerase chain reaction for the diagnosis of cytomegalovirus disease after allogeneic hematopoietic cell transplantation.

Rashidi A, Vij KR, Buller RS, Wylie KM, Storch GA, DiPersio JF.

Am J Hematol. 2017 Feb;92(2):E19-E20. doi: 10.1002/ajh.24609. No abstract available.

20.

Conventional and Regulatory CD4+ T Cells That Share Identical TCRs Are Derived from Common Clones.

Wolf KJ, Emerson RO, Pingel J, Buller RM, DiPaolo RJ.

PLoS One. 2016 Apr 21;11(4):e0153705. doi: 10.1371/journal.pone.0153705. eCollection 2016.

21.

Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve Mice.

Sakala IG, Chaudhri G, Scalzo AA, Eldi P, Newsome TP, Buller RM, Karupiah G.

PLoS Pathog. 2015 Dec 23;11(12):e1005342. doi: 10.1371/journal.ppat.1005342. eCollection 2015 Dec.

22.

Epidemiology, Co-Infections, and Outcomes of Viral Pneumonia in Adults: An Observational Cohort Study.

Crotty MP, Meyers S, Hampton N, Bledsoe S, Ritchie DJ, Buller RS, Storch GA, Micek ST, Kollef MH.

Medicine (Baltimore). 2015 Dec;94(50):e2332. doi: 10.1097/MD.0000000000002332.

23.

The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.

Rapaport AS, Schriewer J, Gilfillan S, Hembrador E, Crump R, Plougastel BF, Wang Y, Le Friec G, Gao J, Cella M, Pircher H, Yokoyama WM, Buller RM, Colonna M.

Immunity. 2015 Dec 15;43(6):1112-24. doi: 10.1016/j.immuni.2015.11.005. Epub 2015 Dec 8.

24.

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.

English PA, Williams JA, Martini JF, Motzer RJ, Valota O, Buller RE.

Future Oncol. 2016 Jan;12(2):175-82. doi: 10.2217/fon.15.290. Epub 2015 Dec 17.

25.

Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship.

Crotty MP, Meyers S, Hampton N, Bledsoe S, Ritchie DJ, Buller RS, Storch GA, Kollef MH, Micek ST.

Crit Care. 2015 Nov 18;19:404. doi: 10.1186/s13054-015-1120-5.

26.

Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.

Kuruganti S, Miersch S, Deshpande A, Speir JA, Harris BD, Schriewer JM, Buller RM, Sidhu SS, Walter MR.

J Biol Chem. 2016 Jan 1;291(1):447-61. doi: 10.1074/jbc.M115.665943. Epub 2015 Nov 6.

27.

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.

Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ.

Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25.

28.

Does azithromycin modify viral load during severe respiratory syncytial virus bronchiolitis?

Beigelman A, Bacharier LB, Baty J, Buller R, Mason S, Schechtman KB, Sajol G, Isaacson-Schmid M, Castro M, Storch GA.

J Allergy Clin Immunol. 2015 Oct;136(4):1129-31. doi: 10.1016/j.jaci.2015.06.011. Epub 2015 Jul 26. No abstract available.

29.

Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation.

Sei JJ, Haskett S, Kaminsky LW, Lin E, Truckenmiller ME, Bellone CJ, Buller RM, Norbury CC.

PLoS Pathog. 2015 Jun 24;11(6):e1004941. doi: 10.1371/journal.ppat.1004941. eCollection 2015 Jun.

30.

Development and Evaluation of an Enterovirus D68 Real-Time Reverse Transcriptase PCR Assay.

Wylie TN, Wylie KM, Buller RS, Cannella M, Storch GA.

J Clin Microbiol. 2015 Aug;53(8):2641-7. doi: 10.1128/JCM.00923-15. Epub 2015 Jun 10.

31.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

32.

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity.

Napier RJ, Norris BA, Swimm A, Giver CR, Harris WA, Laval J, Napier BA, Patel G, Crump R, Peng Z, Bornmann W, Pulendran B, Buller RM, Weiss DS, Tirouvanziam R, Waller EK, Kalman D.

PLoS Pathog. 2015 Mar 30;11(3):e1004770. doi: 10.1371/journal.ppat.1004770. eCollection 2015 Mar.

33.

Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters.

Toth K, Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Sagartz JE, Buller RM, Wold WS.

Viruses. 2015 Mar 23;7(3):1409-28. doi: 10.3390/v7031409.

34.

Deficiency in Th2 cytokine responses exacerbate orthopoxvirus infection.

Sakala IG, Chaudhri G, Eldi P, Buller RM, Karupiah G.

PLoS One. 2015 Mar 9;10(3):e0118685. doi: 10.1371/journal.pone.0118685. eCollection 2015.

35.

Genome sequence of enterovirus D68 from St. Louis, Missouri, USA.

Wylie KM, Wylie TN, Orvedahl A, Buller RS, Herter BN, Magrini V, Wilson RK, Storch GA.

Emerg Infect Dis. 2015 Jan;21(1):184-6. doi: 10.3201/eid2101.141605. No abstract available.

36.

Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.

Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K.

Antiviral Res. 2014 Dec;112:38-46. doi: 10.1016/j.antiviral.2014.10.005. Epub 2014 Oct 15.

PMID:
25453340
37.

Multicenter comparison of laboratory performance in cytomegalovirus and Epstein-Barr virus viral load testing using international standards.

Rychert J, Danziger-Isakov L, Yen-Lieberman B, Storch G, Buller R, Sweet SC, Mehta AK, Cheeseman JA, Heeger P, Rosenberg ES, Fishman JA.

Clin Transplant. 2014 Dec;28(12):1416-23. doi: 10.1111/ctr.12473. Epub 2014 Nov 13.

38.

Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.

Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Dewhurst S, Capella C, Buller RM, Toth K, Wold WS.

Antimicrob Agents Chemother. 2014 Dec;58(12):7171-81. doi: 10.1128/AAC.03860-14. Epub 2014 Sep 15.

39.

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.

Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM.

Antiviral Res. 2014 Nov;111:42-52. doi: 10.1016/j.antiviral.2014.08.003. Epub 2014 Aug 13.

PMID:
25128688
40.

EVM005: an ectromelia-encoded protein with dual roles in NF-κB inhibition and virulence.

van Buuren N, Burles K, Schriewer J, Mehta N, Parker S, Buller RM, Barry M.

PLoS Pathog. 2014 Aug 14;10(8):e1004326. doi: 10.1371/journal.ppat.1004326. eCollection 2014 Aug.

41.

Initial characterization of vaccinia virus B4 suggests a role in virus spread.

Burles K, Irwin CR, Burton RL, Schriewer J, Evans DH, Buller RM, Barry M.

Virology. 2014 May;456-457:108-20. doi: 10.1016/j.virol.2014.03.019. Epub 2014 Apr 4.

42.

National Working Group Meeting on ALK diagnostics in lung cancer.

Cooper W, Fox S, O'Toole S, Morey A, Frances G, Pavlakis N, O'Byrne K, Dettrick A, Leong T, Rathi V, Spagnolo D, Hemmings C, Singh M, Moffat D, Tsao MS, Wilner K, Buller R, Pitman Lowenthal S, Arifeen S, Binko J, Alam M.

Asia Pac J Clin Oncol. 2014 Apr;10 Suppl 2:11-7. doi: 10.1111/ajco.12190.

PMID:
24673736
43.

Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses.

Holechek SA, Denzler KL, Heck MC, Schriewer J, Buller RM, Legrand FA, Verardi PH, Jones LA, Yilma T, Jacobs BL.

PLoS One. 2013 Oct 17;8(10):e77879. doi: 10.1371/journal.pone.0077879. eCollection 2013.

44.

Expression of a non-coding RNA in ectromelia virus is required for normal plaque formation.

Esteban DJ, Upton C, Bartow-McKenney C, Buller R, Chen NG, Schriewer J, Lefkowitz EJ, Wang C.

Virus Genes. 2014 Feb;48(1):38-47.

PMID:
24078045
45.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI.

Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101. Epub 2013 Sep 6. Review.

PMID:
24008432
46.

Immunoproteasome Activation During Early Antiviral Response in Mouse Pancreatic β-cells: New Insights into Auto-antigen Generation in Type I Diabetes?

Freudenburg W, Gautam M, Chakraborty P, James J, Richards J, Salvatori AS, Baldwin A, Schriewer J, Buller RM, Corbett JA, Skowyra D.

J Clin Cell Immunol. 2013 Apr 23;4(2). pii: 141.

47.

Molecular detection of respiratory viruses.

Buller RS.

Clin Lab Med. 2013 Sep;33(3):439-60. doi: 10.1016/j.cll.2013.03.007. Review.

PMID:
23931834
48.
49.

RNA helicase signaling is critical for type i interferon production and protection against Rift Valley fever virus during mucosal challenge.

Ermler ME, Yerukhim E, Schriewer J, Schattgen S, Traylor Z, Wespiser AR, Caffrey DR, Chen ZJ, King CH, Gale M Jr, Colonna M, Fitzgerald KA, Buller RM, Hise AG.

J Virol. 2013 May;87(9):4846-60. doi: 10.1128/JVI.01997-12. Epub 2013 Feb 13.

50.

Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNβ in mouse pancreatic β-cells.

Freudenburg W, Gautam M, Chakraborty P, James J, Richards J, Salvatori AS, Baldwin A, Schriewer J, Buller RM, Corbett JA, Skowyra D.

PLoS One. 2013;8(2):e52408. doi: 10.1371/journal.pone.0052408. Epub 2013 Feb 1.

Supplemental Content

Loading ...
Support Center